Komodo Health | September 29, 2022
Healthcare technology company Komodo Health announced that Lauren Stahl has been appointed as the company’s Vice President and Head of Sales, effective immediately. In this capacity, Stahl’s responsibilities include sales team leadership across Komodo’s entire portfolio of customers, overseeing operational strategy to drive business efficiencies amid year-over-year growth and market expansion.
As Komodo’s new Head of Sales, Stahl will oversee the company’s entire sales organization, with responsibilities for driving business and revenue growth as Komodo scales its offerings and footprint across more than a dozen market segments. Today’s appointment is the latest example of strategic business enhancements being made to power the next phase of innovation, growth, and productivity for the company. The new sales structure will further optimize business development and customer collaboration opportunities as the company introduces new capabilities across its technology platform and software applications.
“Lauren has demonstrated an exceptional track record of deepening customer relationships and unlocking new market and customer sales channels. As Komodo continues to invest in its end-to-end technology platform, having Lauren at the helm of our sales teams will only further accelerate our efforts to put Komodo’s best-in-class technology platform and patient-centric insights in the hands of organizations across Life Sciences, payers, government entities, and more.”
Aswin Chandrakantan, MD, Chief Operating Officer at Komodo Health
Stahl has been driving value for Komodo and its customers for more than three years, quickly rising through the ranks as an individual sales executive to their most recent position as Komodo’s Vice President of Healthcare Sales, where Lauren and their team focused on strategic partnerships with a variety of healthcare innovators to deliver data-driven impact for health plans, digital marketers, consultancies, and more. In this new role overseeing Komodo’s entire sales organization, Stahl will serve as a key sales leader to deliver impact in new market segments and continue to drive hypergrowth revenue for the company.
“I’m humbled and inspired to expand my leadership responsibilities and am eager to continue building on the company’s success and impact in the market,” said Stahl. “Representing Komodo means being a champion for how we are redefining the way healthcare and Life Sciences companies drive innovation into the market. Our technology platform and solutions empower our customers to transform extraordinary amounts of data into rich and meaningful insights that can improve health outcomes.”
Stahl brings nearly 15 years of deep healthcare expertise to this new role, along with extensive financial and sales knowledge drawn from their career on Wall Street and leadership at several digital health companies. Before joining Komodo, Stahl was Head of Customer Success at Datavant, and was previously the CEO and founder of Sparkite, a company focused on addiction and substance abuse aftercare treatment.
About Komodo Health
Komodo Health is a technology platform company creating the new standard for real-world data and analytics by pairing the industry’s most complete view of patient encounters with enterprise software and machine learning that connects the dots between individual patient journeys and large-scale health outcomes. Across Life Sciences, payer, provider, and developers, we help our customers unearth patient-centric insights at scale — marrying clinical data with advanced algorithms and AI-powered software solutions to inform decision making, close gaps in care, address disease burden, and help the enterprise create a more cost-effective, value-driven healthcare system.
AngelEye Health | September 08, 2022
AngelEye Health, a leading provider of family engagement solutions for hospital neonatal and pediatric intensive care units announced the introduction of the company's inaugural NICU technology conversion team. Comprised of some of the healthcare organization's most seasoned onboarding specialists, the unit will help new customers navigate the process of converting from existing solutions to the AngelEye CameraSystem™. Members of the dedicated integration team include project managers, clinical specialists, and systems analysts.
"Exemplary customer support is the cornerstone of the AngelEye Health service offering and has been since day one. As our team continues to quickly add new hospital partners who are converting from other NICU camera solutions, we realized that some of their onboarding needs were unique. We saw an opportunity to proactively ensure that we had the resources in place to address any technical and clinical needs they may have. We are proud to introduce the industry's first NICU technology conversion team, purpose-built to support these transitions every step of the way."
Christopher Rand, CEO of AngelEye Health
Patient and family engagement technology for hospital settings has been growing in acceptance as it presents NICUs and other pediatric units with additional opportunities to support families during their child's time in the hospital. It also fosters an instant and lasting bond with family members even when they can't be at the hospital. In response to this need, AngelEye developed a state-of-the-art CameraSystem™, which brings live-streaming video of the patient to family members anywhere, anytime, on any device. Web-camera technologies provide families with a unique opportunity to connect with their hospitalized children through interactive, real-time technologies. Thus, a cost-efficient pediatric webcam program like AngelEye Health's has the potential to improve the quality of life for participating families by relieving anxiety and cultivating a distant bonding experience.
While the AngelEye onboarding process is always thorough and well-executed, customers who are already familiar with and reliant on cameras in their NICU can now benefit from a specialized level of solution migration support that is unique to their situation. As AngelEye continues to add conversion customers to its portfolio of hospital partners - and at an increasingly accelerated rate - introducing a team of professionals who are well versed in the technology conversion process can add a layer of technical and clinical support to ensure that the transition is seamless and the hospital's NICU care team is up and running on the system quickly and with minimal downtime.
Arkansas Children's Hospital was one of AngelEye’s first NicView conversion projects which involved 90 cameras. Since day one of the technology migration, their hospital team has benefited from the cohesive support from AngelEye’s team of project managers, clinical specialists, and systems analysts, each dedicated to ensuring that the onboarding process was as streamlined and painless as possible.
"AngelEye Health has been very accommodating and willing to work with us and tailor the entire camera system conversion to meet our needs," said Luann Jones, DNP, APRN, NNP-BC, NE-BC, formerly the neonatal services director, Arkansas Children's Hospital. "Every NICU is in a different place at different times, and there's not really a one size fits all approach. Their team was willing to collaborate with us as an institution and as a unit to figure out what really worked best to meet our needs."
For hospitals and health systems interested in learning more about what their own camera system conversion might look like and how the AngelEye NICU technology conversion team can support them through every step of the process, please read the Top 10 Questions from Conversion Partners or schedule a call with one of AngelEye's Account Managers.
About AngelEye Health
AngelEye Health has a deep understanding of the value that both family engagement and family-centered care bring to the neonatal and pediatric intensive care environment. We provide a complete HIPAA-compliant platform to integrate parents simply and seamlessly into the child's care team. Our approach has a proven, positive impact on the quality of the family experience, care delivery workflows for the dedicated bedside team, and patient outcomes. From admission to discharge, AngelEye positively impacts staff, families, and patients along the journey and ultimately to a successful transition home. From bonding, patient progress and treatment communication, feeding, and focused education, AngelEye offers a portfolio of solutions for supporting the highly specialized needs of the NICU and PICU today and of the future. The company was recently named to the Inc. 5,000 listing of America's Fastest-Growing Private Companies.
Healthcare Bluebook and VBA | September 09, 2022
VBA, a leading-edge healthcare technology company, has teamed up with Healthcare Bluebook to incorporate Quantros quality scores for over half a million physicians and hospitals into its VBAnalytics reporting solution.
This move is just one of many exciting enhancements around quality-based care reporting planned in 2022 to make VBAnalytics the premier population health and business insight solution for healthcare payers. VBAnalytics already provides robust analysis and reporting of healthcare utilization and costs and offers insight to help payers make the necessary changes to ensure their health plans are performing effectively.
“As the healthcare industry continues to strive for transparency in both cost and quality, the Quantros quality data is essential for our clients to remain competitive. Being able to benchmark their results against millions of healthcare claims from all regions of the country provides invaluable insight to manage their plan performance.”
Michael Clayton, President and CEO of VBA
With VBAnalytics Value-Based Care Reporting, powered by Quantros, health plans can easily combine cost and quality data to determine which providers are performing the best under their value-based care arrangements. Equipped with this information, payers can make adjustments to their provider networks to ensure that patients have access to the best providers.
The Quantros quality scores include important measures of physician and hospital performance including patient safety, complications from a procedure or hospitalization, mortality, and hospital readmissions. Data is combined among multiple providers to create an episode of care, which allows for a more comprehensive view of the patient’s experience.
VBA has also integrated Healthcare Bluebook’s online shopping tool within its VBAGateway member portal to make it simple for members to access cost and quality information they need with just a few clicks.
“When consumers are equipped with accurate information on cost and quality, everybody wins,” said Clayton. “As consumers become more educated about their healthcare decisions, it will lead to more thoughtful choices that can have a positive ripple effect throughout the healthcare system.”
Providing consumers with better information also helps to reduce the overall cost of healthcare for employers, who cover a significant portion of the healthcare costs for their employees.
VBA is a leading-edge healthcare technology company providing comprehensive solutions to the insurance industry. Uniquely delivered on a secure, cloud-based platform, VBA provides a suite of technology solutions for benefits administration, user experience, customer support, business insight and more.
About Healthcare Bluebook
Healthcare Bluebook's purpose is to protect consumers and companies nationwide from overpriced, low-quality healthcare. Since 2007, Healthcare Bluebook has helped millions of people by making it easy for them to find high-quality care at a Fair Price™.
Tivic Health | October 18, 2022
Tivic Health® Systems, Inc. a commercial-phase health technology company focused on bioelectronic medicine, announced it has entered into a definitive agreement to acquire the Reliefband product line for nausea treatment and all related assets from Reliefband Technologies, LLC.
Reliefband has been an innovator in wearable, FDA-cleared electronic therapeutics for treatment of nausea and vomiting. Reliefband has multiple products available both over-the-counter and by prescription.
“We are incredibly excited to add the full suite of Reliefband products to our commercial portfolio. The Reliefband team successfully pioneered a direct-to-consumer business model for medical products. This acquisition, when combined with our growing direct-to-consumer sales of ClearUP, will significantly accelerate Tivic’s revenue opportunities.”
Jennifer Ernst, CEO of Tivic Health
Recurring nausea impacts approximately 1 in 6 US adults. According to QY Research, nausea treatment is a $2.4B market in the US and $5.5B globally, growing at 6.5% CAGR.
Reliefband’s wrist-worn electronic nerve stimulators have been FDA-cleared for treatment of nausea associated with seven independent clinical indications, including nausea from motion sickness, pregnancy, migraines, anxiety, chemotherapy, various medications and hangovers.
The patented products are backed by 40 peer-reviewed clinical studies and have generated over 3500 Amazon reviews averaging 4+ stars.
Both Reliefband and ClearUP products offer consumers ways to manage health-related conditions without the issues and side effects often associated with medication use. Both are FDA-cleared, highly effective, fast-acting, convenient, and drug-free. Both currently are sold primarily online, and both have received CE Marks allowing international expansion.
In addition to the Reliefband direct-to-consumer branded products, Tivic will also acquire Reliefband’s Reletex-branded prescription nausea treatments. Reletex products are currently distributed by hospitals and medical professionals and are reimbursed under HCPCS code E0765 for certain conditions.
“We look forward to growing Tivic with the addition of clinically proven, revenue-producing bioelectronic products that have seen strong customer adoption and growth,” continued Ernst.
Consideration to be provided by Tivic consists of up to $33.5 million, of which up to $1.5 million can be paid, at the election of Tivic, in restricted common stock of Tivic. Consideration is subject to working capital adjustments, less Reliefband transaction expenses and any indebtedness of Reliefband at closing.
The transaction is expected to be consummated in the fourth quarter of 2022 or first quarter of 2023 after the satisfaction of certain customary closing conditions, including but not limited to securing the financing necessary to pay the purchase price. Additional information on the transaction can be found in a Current Report on Form 8-K filed by Tivic with the Securities and Exchange Commission (SEC).